Market Landscape and Growth Potential Indias GLP-1 receptor agonist market is valued at approximately USD 115 million as of 2024, with projections indicating significant growth driven by increased adoption in diabetes and obesity treatments
Prioritize Lifestyle Fundamentals: Remember that supplements are intended to complement, not replace, a healthy lifestyle
The relatively low discontinuation rate despite side effects affecting 39-44% of users underscores an important point: most adverse events are tolerable and manageable, not severe enough to warrant stopping therapy
- DSIP is a research peptide studied in models involving sleep architecture, stress-response signaling, neuroendocrine regulation, circadian biology, and recovery-related pathways
Currently available GLP-1 receptor agonists in the UK include: Exenatide (injectable formulations) Liraglutide (Victoza for diabetes
LR3 Insulin Like Growth Factor-1 Human Recombinant